Exploring Novel Tetrahydropyrimidine and Fused Pyrimidine‐Based Compounds as DHFR Inhibitors and Antimicrobial Agents: Synthesis, In Vitro, In Vivo, and In Silico Studies
Drug Development Research · 2025
DOI: 10.1002/ddr.70163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Menna M Sherif und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt. Hauptthemen laut MEDLINE: Pyrimidines, Folic Acid Antagonists, Anti-Bacterial Agents, Anti-Infective Agents. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
New series of 2‐imino/oxo‐tetrahydropyrimidines ( 4a‐4j ), and fused pyrimidines ( 5a‐5i and 6a‐6h ) were designed and synthesized as attractive scaffolds to be investigated in vitro and in vivo for antimicrobial activity against gram‐positive Staphylococcus aureus , gram‐negative Escherichia coli and Klebsiella pneumoniae , and fungus Candida albicans . In the in vitro antimicrobial screening using agar diffusion method, compounds 4 d, 4 f, 6a and 6 d showed broad‐spectrum antimicrobial activity against all the tested strains when compared to levofloxacin as a reference drug. Moreover, compound 4 f showed higher antibacterial activity against all the tested microorganisms with MIC = 22–45 µM compared with levofloxacin with MIC = 50‐ > 708 µM. Compound 5 g exhibited lower IC 50 than that of reference trimethoprim (TMP) towards the DHFR enzyme inhibition. Additionally, compounds 4 d, 4 f, 4 g, 6 d and 6 f had kept the superiority over the reference drug with IC 50 ranging from 4.10 to 4.77 µM. Compounds 4 f and 6a were subjected to in vivo evaluation for their antibacterial activity. They caused a significant reduction in abscess volume and area in the skin of mice inoculated with S. aureus . Moreover, compound 4 f had reduced the immune‐expression of interleukin‐1β in the isolated tissues of the infected skin. Molecular docking results were in a good agreement with the DHFR enzyme assay results and justified the binding profiles and affinities profile of all tested compounds. Conclusively, compounds 4 d, 4 f, 5 g, 6a and 6 d are very promising candidates for further antimicrobial studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Kut, Kut, Iraq.
- Department of Microbiology and Biotechnology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
- Department of Pharmacology and Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus-University Egypt, New Damietta, Egypt.
ORCID-Profile: Menna M Sherif
Zitieren
APA
Sherif, M. M., Mansour, B., El-Antrawy, M. A., Abdelaziz, H. A., Badr, S. M. I., & Nasr, M. N. A. (2025). Exploring Novel Tetrahydropyrimidine and Fused Pyrimidine‐Based Compounds as DHFR Inhibitors and Antimicrobial Agents: Synthesis, In Vitro, In Vivo, and In Silico Studies. Drug Development Research. https://doi.org/10.1002/ddr.70163
Vancouver
Sherif MM, Mansour B, El-Antrawy MA, Abdelaziz HA, Badr SMI, Nasr MNA. Exploring Novel Tetrahydropyrimidine and Fused Pyrimidine‐Based Compounds as DHFR Inhibitors and Antimicrobial Agents: Synthesis, In Vitro, In Vivo, and In Silico Studies. Drug Development Research. 2025. doi:10.1002/ddr.70163
BibTeX
@article{Sherif2025,
author = {Sherif, Menna M and Mansour, Basem and El-Antrawy, May A and Abdelaziz, Heba A and Badr, Sahar M I and Nasr, Magda N A},
title = {Exploring Novel Tetrahydropyrimidine and Fused Pyrimidine‐Based Compounds as DHFR Inhibitors and Antimicrobial Agents: Synthesis, In Vitro, In Vivo, and In Silico Studies},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70163}
}
EUVIMED